--- title: "Adalank: Dosing & Vendor Prices | BodyHackGuide" description: "Adalank: dosing protocols, mechanism & side effects. Compare current vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Adalank" } ] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Adalank", "description": "Adalank is a hybrid research peptide combining structural elements of Adamax (the adamantyl-modified Semax analog) and Selank (the anxiolytic Pro-Gly-Pro tuftsin analog). Vendors positioned it around 2022-2024 as a single-molecule replacement for users running parallel Adamax + Selank protocols — covering both cognitive enhancement and anxiolysis without two separate intranasal or subcutaneous regimens. Important naming caveat. \"Adalank\" is used by some vendors for the Adamax/Selank hybrid described here. Other vendors use the same name for N-acetyl-Selank-amidate (Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2, ~792.9 Da) — a different compound that is just Selank with acetyl + amide stability caps and no adamantane modification. If you're sourcing Adalank, confirm with the vendor which interpretation their product matches, because the dosing, half-life, and mechanism differ meaningfully between the two. Evidence base. Peer-reviewed literature for Adalank specifically — under either interpretation — is essentially nonexistent. PubMed returns zero hits for \"Adalank\" as of 2026. All pharmacological claims are extrapolated from the constituent compounds: Semax (~12 published studies, mostly Russian), Selank (~88 published studies including formal anxiolytic trials), Adamax (zero direct publications), and the broader adamantane-CNS modification literature (amantadine, memantine). Where it sits. Treat Adalank as a vendor-formulated convenience peptide — Adamax-tier cognitive effects layered onto Selank-tier anxiolytic effects, with no direct head-to-head data versus running the two compounds separately. The hybrid is not a clinical drug, has no FDA or regulatory approval anywhere, and exists primarily as a research peptide sold by a handful of Western vendors (Limitless Life Nootropics, BioLongevity Labs, Olympic Peptide, Pure Lab Peptides). Researchers should approach claims of \"30-100x more potent than Selank/Semax\" found on vendor sites as vendor-marketing only — there is no published comparison to substantiate the potency multipliers.", "lastReviewed": "2026-06-01T23:07:40.110178+00:00", "url": "https://www.bodyhackguide.co/compound/adalank", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Adalank", "alternateName": [ "Adamax-Selank", "Adamax + Selank Hybrid", "Ada-Lank" ], "description": "Adalank is a hybrid research peptide combining structural elements of Adamax (the adamantyl-modified Semax analog) and Selank (the anxiolytic Pro-Gly-Pro tuftsin analog). Vendors positioned it around 2022-2024 as a single-molecule replacement for users running parallel Adamax + Selank protocols — covering both cognitive enhancement and anxiolysis without two separate intranasal or subcutaneous regimens. Important naming caveat. \"Adalank\" is used by some vendors for the Adamax/Selank hybrid described here. Other vendors use the same name for N-acetyl-Selank-amidate (Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2, ~792.9 Da) — a different compound that is just Selank with acetyl + amide stability caps and no adamantane modification. If you're sourcing Adalank, confirm with the vendor which interpretation their product matches, because the dosing, half-life, and mechanism differ meaningfully between the two. Evidence base. Peer-reviewed literature for Adalank specifically — under either interpretation — is essentially nonexistent. PubMed returns zero hits for \"Adalank\" as of 2026. All pharmacological claims are extrapolated from the constituent compounds: Semax (~12 published studies, mostly Russian), Selank (~88 published studies including formal anxiolytic trials), Adamax (zero direct publications), and the broader adamantane-CNS modification literature (amantadine, memantine). Where it sits. Treat Adalank as a vendor-formulated convenience peptide — Adamax-tier cognitive effects layered onto Selank-tier anxiolytic effects, with no direct head-to-head data versus running the two compounds separately. The hybrid is not a clinical drug, has no FDA or regulatory approval anywhere, and exists primarily as a research peptide sold by a handful of Western vendors (Limitless Life Nootropics, BioLongevity Labs, Olympic Peptide, Pure Lab Peptides). Researchers should approach claims of \"30-100x more potent than Selank/Semax\" found on vendor sites as vendor-marketing only — there is no published comparison to substantiate the potency multipliers.", "activeIngredient": "Adalank", "administrationRoute": "Intranasal, Subcutaneous", "mechanismOfAction": "Adamax component - BDNF and TrkB Pathway The Adamax side of the molecule is hypothesized to upregulate brain-derived neurotrophic factor (BDNF) expression in the hippocampus and modulate TrkB receptor sensitivity. This is the proposed mechanism for the cognitive enhancement signal observed in community protocols - sustained focus, memory consolidation, and motivation. Adamax component - D2 Receptor Modulation Adamax also reportedly modulates dopamine D2 receptor sensitivity in ventral tegmental area / nucleus accumbens motivation circuits. This dopaminergic effect contributes to the \"drive\" and reward-system response some users report - distinct from but overlapping with stimulant-class effects. Selank component - GABAergic Anxiolysis The Selank moiety carries Selank's documented anxiolytic profile: GABAergic modulation without sedation, hippocampal BDNF upregulation (overlapping with the Adamax mechanism), and serotonergic/enkephalin-like effects. Selank does not produce benzodiazepine-like tolerance or withdrawal in published Russian outpatient trials - this is one of the central selling points of the family. Selank component - Immune Modulation Selank exhibits tuftsin-like activity: Selank's N-terminal Thr-Lys-Pro-Arg sequence IS tuftsin, a natural immunomodulatory tetrapeptide, and Selank is a synthetic analog built on that tuftsin core [PMID:31625062]. The C-terminal Pro-Gly-Pro is a synthetic stabilizing extension added to slow enzymatic breakdown - it is not derived from tuftsin. Through the tuftsin portion, Selank modulates cytokine balance and produces mild immune-support effects. Whether this carries over to the hybrid Adalank molecule depends on the specific bond chemistry used by the vendor - confirm with the supplier. Combined effect profile Users report an \"alert calm\" subjective state - Adamax-driven motivation and cognitive clarity layered onto Selank-driven anxiolysis. This is similar to running NA-Semax + Selank or P-21 + Selank stacks, but consolidated into one molecule with (claimed) extended half-life from the adamantane modification. Blood-brain-barrier delivery The adamantyl group inherited from the Adamax side is the same lipophilic cage structure used in amantadine and memantine to improve BBB permeability. This is hypothesized to lower the effective peripheral dose required to achieve central effects - though no direct PK comparison vs Adamax or Selank alone has been published. Receptor binding duration The ~72-hour functional duration after a single dose is an unverified community/vendor claim - no pharmacokinetic study has measured it. It is extrapolated from the parent Adamax marketing claims and used to justify every-other-day dosing schedules, but it should be treated as anecdote, not measured PK.", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What's the difference between Adalank and just running Adamax + Selank together?", "acceptedAnswer": { "@type": "Answer", "text": "Pharmacologically, the goal is the same - Adamax's cognitive / motivational effects layered onto Selank's anxiolytic effects. The hybrid molecule is sold on a convenience argument (one product, one protocol) and a claimed PK argument (the adamantyl group extends receptor binding versus two separate peptides). There is no head-to-head data published comparing the hybrid to co-administration of the parents. Treat the convenience as real and the PK advantage as plausible-but-unverified." } }, { "@type": "Question", "name": "Why are there no PubMed studies for Adalank?", "acceptedAnswer": { "@type": "Answer", "text": "Adalank is a vendor-formulated research peptide, not a clinical drug. It was not developed in an academic pipeline. Its components (Adamax and Selank) have separate literature bases, but the hybrid itself has zero direct publications. Effects, dosing, and safety are inferred entirely from the constituent compounds and community protocols." } }, { "@type": "Question", "name": "Is Adalank the same thing as N-acetyl-Selank-amidate?", "acceptedAnswer": { "@type": "Answer", "text": "Sometimes - vendors are inconsistent. Some sell 'Adalank' as the Adamax+Selank hybrid described in this entry. Others use the same name for N-acetyl-Selank-amidate (Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2), which is just Selank with acetyl + amide stability caps and no adamantane group. Confirm with the supplier which interpretation their product matches because the dosing, half-life, and mechanism differ." } }, { "@type": "Question", "name": "Intranasal or subcutaneous?", "acceptedAnswer": { "@type": "Answer", "text": "Both are documented. Intranasal is more common for users who already use Selank or Semax that way. Subcutaneous is favored when the vendor's product is larger / more lipophilic and absorbs poorly through nasal mucosa. The choice doesn't dramatically change the effect profile - both routes reach central targets. Subcutaneous gives faster onset; intranasal gives more controlled dose titration." } }, { "@type": "Question", "name": "How long does a cycle last and why washouts?", "acceptedAnswer": { "@type": "Answer", "text": "Typical cycle is 21-30 days on, 7-14 days off. The washout is precautionary - Adalank modulates both BDNF / TrkB / D2 (from the Adamax side) and GABA / serotonergic systems (from the Selank side). Continuous chronic stimulation of any single receptor system risks desensitization. Cycling avoids that risk and preserves response across multiple cycles. There is no formal data establishing the optimal cycle length - these are community-developed precautions." } }, { "@type": "Question", "name": "Can Adalank be used long-term?", "acceptedAnswer": { "@type": "Answer", "text": "There is no long-term safety data - none. Multi-month and multi-year exposure consequences are uncharacterized. Cycling protocols are a precautionary mitigation, not validation of long-term safety. If used across multiple cycles, monitor for mood changes, sleep disruption, and any cardiovascular shifts." } }, { "@type": "Question", "name": "What does Adalank feel like subjectively?", "acceptedAnswer": { "@type": "Answer", "text": "Most users report an 'alert calm' state - focused and motivated without the anxiety that often comes with stimulant-class compounds, and calm without the sedation that often comes with GABAergic compounds. Subjective effects build over 7-10 days. Peak is typically reported in weeks 2-3 of a cycle. Effects taper over 1-2 weeks following the last dose. The ~72-hour 'receptor binding window' often cited for Adalank is an unverified community/vendor claim with no pharmacokinetic data behind it - it is not a measured figure, so treat the taper timeline as anecdotal." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Fadalank) 100K+ researchers trust BodyHackGuide. Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 3. [Compounds](/compare) 5. Adalank [🛒 Where to buy Adalank](/buy/adalank)[🏷️ Adalank coupon codes](/coupons/adalank)[📋 Adalank protocol](/protocol/adalank)[🔄 Alternatives to Adalank](/alternatives-to/adalank)[⚠️ Adalank side effects](/side-effects/adalank) 1. [Home](/) 3. [Compounds](/compare) 5. Adalank # Adalank Nootropic Peptide Preclinical / Research compound Download PDF Also known as: Adamax-Selank, Adamax + Selank Hybrid, Ada-Lank Adalank is a hybrid research peptide combining structural elements of Adamax (the adamantyl-modified Semax analog) and Selank (the anxiolytic Pro-Gly-Pro tuftsin analog). Vendors positioned it around 2022-2024 as a single-molecule replacement for users running parallel Adamax + Selank protocols — covering both cognitive enhancement and anxiolysis without two separate intranasal or subcutaneous regimens. Important naming caveat. "Adalank" is used by some vendors for the Adamax/Selank hybrid described here. Half-Life: The commonly cited ~72-hour "functional duration" is an unverified community/vendor claim, not a measured value - no pharmacokinetic study of Adalank has ever been run. The figure is extrapolated from parent Adamax marketing claims. Actual serum half-life is unknown; there is no published PK data. Route: Intranasal, Subcutaneous MW: Molecular weight not established - Adalank is an undefined vendor construct with no verified value. As a rough estimate, a Semax-analog + Selank hybrid (the two named peptides plus an adamantyl group, minus water at the linkage) would fall around 1600-1900 Da depending on the linker and adamantyl chemistry. No vendor publishes a verified mass-spectrometry spectrum, and older "~935-1300 Da" figures are inconsistent with the stated sequence and should be disregarded. CAS: Not assigned (research peptide, no CAS registry entry as of 2026) Last reviewed: Jun 1, 2026 [ Nootropic Peptide Category ](/wiki#cat-nootropic-peptide) Preclinical / Research compound Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare PricesRelated ## Overview ### At A Glance Mechanism Adamax component - BDNF and TrkB Pathway… Half-Life The commonly cited ~72-hour "functional duration" is an unverified community/vendor claim, not a measured value - no pharmacokinetic study of Adalank has ever been run. The figure is extrapolated from parent Adamax marketing claims. Actual serum half-life is unknown; there is no published PK data. Dosing Once or twice daily during cycles. Every-other-day protocols also documented. Dose Range 200-1200 mcg per dose (intranasal or subcutaneous), 1-2x dailymcg Routes Intranasal Subcutaneous Common Vials 5mgmg 10mgmg Potential Benefits Combined cognitive enhancement and anxiolysis in one molecule Adamax-tier BDNF / TrkB upregulation (inferred from constituent) Selank-tier GABAergic anxiolysis without sedation (inferred from constituent) Claimed sustained duration (~72 hours) used to justify every-other-day dosing - an unverified community/vendor claim, not measured pharmacokinetics Improved blood-brain-barrier penetration vs unmodified Selank or Semax (adamantane chemistry) Subjective "alert calm" - motivation without anxiety, focus without overstimulation No reported benzodiazepine-like tolerance or withdrawal (inferred from Selank parent) Safety Notes Common Mild headache (often dose-related and self-limiting) Transient insomnia if dosed in the evening Mild nasal irritation (intranasal route) Increased dream activity Subjective mood elevation (typically positive) ### Mechanism of Action **Adamax component - BDNF and TrkB Pathway** The Adamax side of the molecule is hypothesized to upregulate brain-derived neurotrophic factor (BDNF) expression in the hippocampus and modulate TrkB receptor sensitivity. This is the proposed mechanism for the cognitive enhancement signal observed in community protocols - sustained focus, memory consolidation, and motivation. **Adamax component - D2 Receptor Modulation** Adamax also reportedly modulates dopamine D2 receptor sensitivity in ventral tegmental area / nucleus accumbens motivation circuits. This dopaminergic effect contributes to the "drive" and reward-system response some users report - distinct from but overlapping with stimulant-class effects. **Selank component - GABAergic Anxiolysis** The Selank moiety carries Selank's documented anxiolytic profile: GABAergic modulation without sedation, hippocampal BDNF upregulation (overlapping with the Adamax mechanism), and serotonergic/enkephalin-like effects. Selank does not produce benzodiazepine-like tolerance or withdrawal in published Russian outpatient trials - this is one of the central selling points of the family. **Selank component - Immune Modulation** Selank exhibits tuftsin-like activity: Selank's N-terminal Thr-Lys-Pro-Arg sequence IS tuftsin, a natural immunomodulatory tetrapeptide, and Selank is a synthetic analog built on that tuftsin core \[PMID:31625062\]. The C-terminal Pro-Gly-Pro is a synthetic stabilizing extension added to slow enzymatic breakdown - it is not derived from tuftsin. Through the tuftsin portion, Selank modulates cytokine balance and produces mild immune-support effects. Whether this carries over to the hybrid Adalank molecule depends on the specific bond chemistry used by the vendor - confirm with the supplier. **Combined effect profile** Users report an "alert calm" subjective state - Adamax-driven motivation and cognitive clarity layered onto Selank-driven anxiolysis. This is similar to running NA-Semax + Selank or P-21 + Selank stacks, but consolidated into one molecule with (claimed) extended half-life from the adamantane modification. **Blood-brain-barrier delivery** The adamantyl group inherited from the Adamax side is the same lipophilic cage structure used in amantadine and memantine to improve BBB permeability. This is hypothesized to lower the effective peripheral dose required to achieve central effects - though no direct PK comparison vs Adamax or Selank alone has been published. **Receptor binding duration** The ~72-hour functional duration after a single dose is an unverified community/vendor claim - no pharmacokinetic study has measured it. It is extrapolated from the parent Adamax marketing claims and used to justify every-other-day dosing schedules, but it should be treated as anecdote, not measured PK. ### Overview Adalank is a **hybrid research peptide** combining structural elements of [Adamax](/compound/adamax) (the adamantyl-modified Semax analog) and [Selank](/compound/selank) (the anxiolytic Pro-Gly-Pro tuftsin analog). Vendors positioned it around 2022-2024 as a single-molecule replacement for users running parallel Adamax + Selank protocols — covering both cognitive enhancement and anxiolysis without two separate intranasal or subcutaneous regimens. **Important naming caveat.** "Adalank" is used by some vendors for the Adamax/Selank hybrid described here. Other vendors use the same name for **N-acetyl-Selank-amidate (Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2, ~792.9 Da)** — a different compound that is just Selank with acetyl + amide stability caps and no adamantane modification. If you're sourcing Adalank, confirm with the vendor which interpretation their product matches, because the dosing, half-life, and mechanism differ meaningfully between the two. **Evidence base.** Peer-reviewed literature for Adalank specifically — under either interpretation — is essentially nonexistent. PubMed returns zero hits for "Adalank" as of 2026. All pharmacological claims are extrapolated from the constituent compounds: Semax (~12 published studies, mostly Russian), Selank (~88 published studies including formal anxiolytic trials), Adamax (zero direct publications), and the broader adamantane-CNS modification literature (amantadine, memantine). **Where it sits.** Treat Adalank as a vendor-formulated convenience peptide — Adamax-tier cognitive effects layered onto Selank-tier anxiolytic effects, with no direct head-to-head data versus running the two compounds separately. The hybrid is _not_ a clinical drug, has no FDA or regulatory approval anywhere, and exists primarily as a research peptide sold by a handful of Western vendors (Limitless Life Nootropics, BioLongevity Labs, Olympic Peptide, Pure Lab Peptides). Researchers should approach claims of "30-100x more potent than Selank/Semax" found on vendor sites as vendor-marketing only — there is no published comparison to substantiate the potency multipliers. ### Potential Research Fields Cognitive enhancement Anxiolysis BDNF research Dopaminergic modulation Hybrid peptide engineering Nootropic peptides ## Chemical Information IUPAC Name No standardized IUPAC name. Hybrid construct combining N-acetyl-Met-Glu-His-Phe-Pro-Gly-Pro-Ala-Gly-amide (adamantyl-modified) with Thr-Lys-Pro-Arg-Pro-Gly-Pro. CAS Number Not assigned (research peptide, no CAS registry entry as of 2026) Molecular Formula Approximately C58H86N18O14 (calculated from hybrid construct; exact formula depends on linker chemistry) Molecular Mass Not established by mass spectrometry. A Semax-analog + Selank hybrid (adamantyl-modified) would be roughly 1600-1900 Da by summing the constituent peptides minus water at the linkage, but no vendor publishes a verified MS spectrum, so treat any single figure as unconfirmed. The previously listed "~1268 g/mol" value is inconsistent with the stated sequence. Amino Acid Sequence Hybrid: Adamax (Ac-MEHFPGPAG-NH2, adamantyl-modified) linked to Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) backbone. Exact bond chemistry varies by vendor — confirm with supplier. ## Dosing & Protocols ### Dosing Summary Dose 200-1200 mcg per dose (intranasal or subcutaneous), 1-2x daily Route Intranasal or subcutaneous Frequency Once or twice daily during cycles. Every-other-day protocols also documented. Duration 21-30 day cycles, with 7-14 day washouts between cycles. Avoid chronic continuous dosing. ### Titration Schedule Step Weeks Dose Purpose Week 1 — 200-400 mcg/day Assess tolerance, baseline subjective shift Weeks 2-3 — 400-800 mcg/day Therapeutic dosing, peak subjective effects Weeks 4 (advanced) — 800-1200 mcg/day Optimization for non-responders; not required for most users Washout — 0 Receptor resensitization, avoid chronic tolerance ### Beginner Protocol ### Intermediate Protocol ### Advanced Protocol ### Reconstitution Guide Solvent bacteriostatic water Volume 2 mL Storage Refrigerate (2-8°C) Stability Up to 30 days refrigerated Common Vial Sizes 5mg 10mg Instructions 1 Clean the vial stopper with an alcohol swab 2 Draw 2 mL bacteriostatic water into a syringe 3 Insert needle into vial and slowly inject solvent down the side wall 4 Gently swirl (never shake) until fully dissolved 5 Store refrigerate (2-8°c) after reconstitution Important - • Never shake — gently swirl to preserve peptide bonds - • Use bacteriostatic water for multi-dose vials - • Discard if solution appears cloudy or discolored [Open Reconstitution Calculator](/tools/reconstitution) ### Detailed Reconstitution Instructions ### Stacking Notes ### Additional Dosage Notes [Full Adalank Dosing Guide](/guides/dosage/adalank) ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research [PubMed Results](https://pubmed.ncbi.nlm.nih.gov/?term=Adalank%20peptide)Last updated: June 1, 2026 ### Key Research Findings **No completed clinical trials for Adalank exist.** PubMed search for "Adalank" returns zero results as of 2026. ClinicalTrials.gov contains no registered trials. The compound exists outside any formal clinical development pipeline. **Evidence by proxy:** - **Adamax component:** zero direct studies; effects inferred from Semax literature and adamantane-CNS modification literature (amantadine, memantine pharmacology) - **Selank component:** ~88 PubMed entries on parent Selank, including: — Russian outpatient anxiolytic trial vs medazepam - Multiple animal model studies of stress-resilience and BDNF modulation - Russian regulatory approval as anxiolytic in 2009 (Selemax / Selank brand) - **P-21 / N-acetyl-Semax-amidate (related family compound):** limited published Western studies; mostly Russian institute work on the parent Semax **What this means for researchers:** Treat Adalank as a vendor-formulated convenience product with pharmacology inferred entirely from constituent compounds. Do not cite "Adalank studies" — there are none. When publishing or sharing research findings using Adalank, the appropriate framing is _Adamax + Selank hybrid_ and the appropriate citation set is the Semax + Selank + adamantane-CNS literature. **Notable absence:** No head-to-head efficacy or pharmacokinetic comparison vs Adamax + Selank co-administered separately. The "convenience advantage" is plausible but unverified. The "extended duration" claim is plausible (the adamantyl group on the Adamax half-shoulders the half-life extension) but unverified by independent measurement. **Vendor claims to discount:** - "30-100x more potent than Selank or Semax" — no published source. Treat as vendor-marketing. - "Better BBB penetration than Adamax or Selank alone" — plausible based on adamantane chemistry but not directly measured. - "Clinically proven anxiolysis" — false. No clinical proof exists for Adalank itself; Selank parent has Russian regulatory approval but Adalank does not. ### Safety & Side Effects **Reported (anecdotal, no formal trials):** - **Headache** — most commonly reported side effect, typically dose-related and self-limiting within 1-3 days. More common with intranasal route at higher doses. - **Transient insomnia** — if dosed in the evening. Restrict to morning / early afternoon if sleep is sensitive. - **Nasal irritation** — intranasal route only. Usually resolves within the first week of use or with dilution to a lower per-spray concentration. - **Mild mood elevation / irritability** — typically positive but can tip into restlessness at higher doses or in users sensitive to dopaminergic stimulation. - **Mild BP elevation** — anecdotal. Monitor if you have baseline hypertension. - **Increased dream activity** — common with Selank-family compounds and reported with Adalank as well. Usually benign. **No reported serious adverse events** in publicly available community datasets — but this is not a formal safety conclusion. The absence of SAEs reflects unregulated underreporting, not formal safety clearance. **No long-term safety data exists.** Multi-month or multi-year exposure consequences are entirely uncharacterized. Cycling protocols (21-30 days on, 7-14 days off) are a precautionary mitigation, not a validated safe-use pattern. **If side effects emerge:** - Headache or insomnia: lower dose by 50%, restrict to morning dosing - Mood instability or anxiety: discontinue immediately and consult a clinician - Persistent nasal irritation: switch to subcutaneous route or discontinue - BP elevation: discontinue and monitor **Reporting:** Adalank does not appear in FDA MedWatch or any major adverse event database. Community reporting via Reddit (r/Nootropics, r/Peptides) is the de facto safety signal but is heavily biased by self-selection. [Browse Studies on PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=Adalank%20peptide) ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Interaction Matrix All(11) Compatible(3) Caution(6) Avoid(2) Adamax Avoid Selank Avoid Semax Caution P-21 Caution N-Acetyl Semax Amidate Caution Cerebrolysin Synergistic Dihexa Synergistic BPC-157 Compatible Benzodiazepines Caution MAOIs Caution Wellbutrin (bupropion) Caution ### Contraindications **Absolute:** - Pregnancy and lactation — no safety data, multi-mechanism profile creates compounded unknowns - Active psychiatric instability (acute mania, psychosis) — dopaminergic component may exacerbate - Pediatric use — not characterized in any age group below adult - Known hypersensitivity to peptide injections or any constituent peptide **Relative (caution):** - Bipolar disorder (any phase) — dopaminergic D2 modulation may destabilize mood cycling - Uncontrolled hypertension — community reports of mild BP elevation at higher doses - Concurrent benzodiazepines or other GABAergic sedatives — additive effects on alertness - Concurrent MAOI therapy — theoretical interaction via dopaminergic component - Recent head trauma — no data; precautionary - Sleep disorders — late-day dosing can worsen insomnia; restrict dosing to before noon if sleep is fragile **Substance interactions to avoid:** - Stimulants (amphetamines, methylphenidate) — additive dopaminergic load - Recreational dopaminergic compounds — same concern **Stack overlaps to avoid:** - Semax, Selank, Adamax, P-21 at full simultaneous doses — Adalank already contains the Adamax + Selank pharmacophores Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. [Sign in for alerts ](/auth) No listings found for Adalank. Get Adalank Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Adalank. [Sign in](/auth) ### Related Compounds [View All](/wiki) [ ### Adamax Nootropic Peptide Preclinical / Research compound Adamax is a synthetic nonapeptide (Ac-MEHFPGPAG-NH2) classified as a designer analog of Semax. t½ No pharmacokinetic data. Community reports describe a subjectively long duration of effect (~2-3 days), supporting every-other-day or 3x/week dosing; serum half-life not characterized. 500-2000 mcg subcutaneous (community research dosing) Preclinical View Profile ](/compound/adamax)[ ### Cerebrolysin Nootropic Peptide Clinical Cerebrolysin is a porcine brain-derived peptide complex developed by EVER Neuro Pharma (Austria) — a low-molecular-weight neurotrophic preparation containing a mixture of free amino acids and bioactive peptides extracted from purified pig brain proteins. t½ ~2-4 hours (multi-component peptide mix) 85 PubMed View Profile ](/compound/cerebrolysin)[ ### Cortexin Nootropic Peptide Marketed in Russia/CIS (Geropharm); human clinical use with limited-quality evidence (small, mostly Russian-language studies; no Western RCT; not FDA/EMA approved) Cortexin is a purified peptide preparation extracted from cattle and pig cerebral cortex tissue — a low-molecular-weight neuropeptide complex used clinically in Russia and Eastern Europe for cognitive impairment, post-stroke recovery, encephalopathy, attention disorders, and pediatric developmental conditions. Like Cerebrolysin, Cortexin is positioned as a broad-spectrum neurotrophic preparation supplying bioactive peptides that mimic endogenous neurotrophic factors. t½ ~2-3 hours (estimated from analog peptide preparations) 18 PubMed View Profile ](/compound/cortexin)[ ### NA-Semax Nootropic Peptide Preclinical NA-Semax is the N-acetyl-l-aspartyl variant of Semax — the original ACTH(4-7) Pro-Gly-Pro analog developed at the Russian Academy of Sciences in the 1990s. t½ ~20-30 minutes (intranasal, estimated from analog data) 3 PubMed View Profile ](/compound/na-semax)[ ### NA-Semax Amidate Nootropic Peptide Preclinical NA-Semax Amidate is the C-terminally amidated NA-Semax — the carboxylic acid at the peptide's C-terminus is replaced with an amide group (-NH2), which is reported to further extend metabolic half-life by resisting carboxypeptidase cleavage in addition to the aminopeptidase resistance the N-acetyl group already provides. The practical effect is a peptide with dosing-frequency use: where standard Semax often requires 3-4 daily doses to maintain effect, NA-Semax Amidate is reported (in vendor monographs and community usage) to maintain subjective effects on a 1-2x daily schedule. t½ ~30-45 minutes (estimated, longer than standard Semax) 2 PubMed View Profile ](/compound/na-semax-amidate)[ ### P-21 Nootropic Peptide Preclinical P-21 is a synthetic cyclic dipeptide — Cyclo(L-prolyl-glycine) — derived from the Selank/Semax C-terminal Pro-Gly-Pro motif. t½ Not formally characterized in published work. P021 has only been studied in rodents (oral/dietary and subcutaneous dosing); no human pharmacokinetic data exist. 4 PubMed View Profile ](/compound/p21) [ View Full Dosage Guide → Protocols, calculator & safety for Adalank ](/guides/dosage/adalank) ### Research Score 60 0 PubMed results ### Quality Indicators Data Completeness 75% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Results Interactions Vendor Listings ### Quick Facts Half-Life The commonly cited ~72-hour "functional duration" is an unverified community/vendor claim, not a measured value - no pharmacokinetic study of Adalank has ever been run. The figure is extrapolated from parent Adamax marketing claims. Actual serum half-life is unknown; there is no published PK data. Molecular Weight Not established by mass spectrometry. A Semax-analog + Selank hybrid (adamantyl-modified) would be roughly 1600-1900 Da by summing the constituent peptides minus water at the linkage, but no vendor publishes a verified MS spectrum, so treat any single figure as unconfirmed. The previously listed "~1268 g/mol" value is inconsistent with the stated sequence. Administration Intranasal, Subcutaneous CAS Number Not assigned (research peptide, no CAS registry entry as of 2026) Trial Phase Preclinical / Research compound ### Safety Profile Common Side Effects - • Mild headache (often dose-related and self-limiting) - • Transient insomnia if dosed in the evening - • Mild nasal irritation (intranasal route) - • Increased dream activity - • Subjective mood elevation (typically positive) [Full Dosage Guide](/guides/dosage/adalank)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What's the difference between Adalank and just running Adamax + Selank together? Pharmacologically, the goal is the same - Adamax's cognitive / motivational effects layered onto Selank's anxiolytic effects. The hybrid molecule is sold on a convenience argument (one product, one protocol) and a claimed PK argument (the adamantyl group extends receptor binding versus two separate peptides). There is no head-to-head data published comparing the hybrid to co-administration of the parents. Treat the convenience as real and the PK advantage as plausible-but-unverified. Why are there no PubMed studies for Adalank? Adalank is a vendor-formulated research peptide, not a clinical drug. It was not developed in an academic pipeline. Its components (Adamax and Selank) have separate literature bases, but the hybrid itself has zero direct publications. Effects, dosing, and safety are inferred entirely from the constituent compounds and community protocols. Is Adalank the same thing as N-acetyl-Selank-amidate? Sometimes - vendors are inconsistent. Some sell 'Adalank' as the Adamax+Selank hybrid described in this entry. Others use the same name for N-acetyl-Selank-amidate (Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2), which is just Selank with acetyl + amide stability caps and no adamantane group. Confirm with the supplier which interpretation their product matches because the dosing, half-life, and mechanism differ. Intranasal or subcutaneous? Both are documented. Intranasal is more common for users who already use Selank or Semax that way. Subcutaneous is favored when the vendor's product is larger / more lipophilic and absorbs poorly through nasal mucosa. The choice doesn't dramatically change the effect profile - both routes reach central targets. Subcutaneous gives faster onset; intranasal gives more controlled dose titration. How long does a cycle last and why washouts? Typical cycle is 21-30 days on, 7-14 days off. The washout is precautionary - Adalank modulates both BDNF / TrkB / D2 (from the Adamax side) and GABA / serotonergic systems (from the Selank side). Continuous chronic stimulation of any single receptor system risks desensitization. Cycling avoids that risk and preserves response across multiple cycles. There is no formal data establishing the optimal cycle length - these are community-developed precautions. Can Adalank be used long-term? There is no long-term safety data - none. Multi-month and multi-year exposure consequences are uncharacterized. Cycling protocols are a precautionary mitigation, not validation of long-term safety. If used across multiple cycles, monitor for mood changes, sleep disruption, and any cardiovascular shifts. What does Adalank feel like subjectively? Most users report an 'alert calm' state - focused and motivated without the anxiety that often comes with stimulant-class compounds, and calm without the sedation that often comes with GABAergic compounds. Subjective effects build over 7-10 days. Peak is typically reported in weeks 2-3 of a cycle. Effects taper over 1-2 weeks following the last dose. The ~72-hour 'receptor binding window' often cited for Adalank is an unverified community/vendor claim with no pharmacokinetic data behind it - it is not a measured figure, so treat the taper timeline as anecdotal. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### Adamax Nootropic Peptide Preclinical / Research compound Adamax is a synthetic nonapeptide (Ac-MEHFPGPAG-NH2) classified as a designer analog of Semax. t½ No pharmacokinetic data. Community reports describe a subjectively long duration of effect (~2-3 days), supporting every-other-day or 3x/week dosing; serum half-life not characterized. 500-2000 mcg subcutaneous (community research dosing) Preclinical View Profile ](/compound/adamax)[ ### Cerebrolysin Nootropic Peptide Clinical Cerebrolysin is a porcine brain-derived peptide complex developed by EVER Neuro Pharma (Austria) — a low-molecular-weight neurotrophic preparation containing a mixture of free amino acids and bioactive peptides extracted from purified pig brain proteins. t½ ~2-4 hours (multi-component peptide mix) 85 PubMed View Profile ](/compound/cerebrolysin)[ ### Cortexin Nootropic Peptide Marketed in Russia/CIS (Geropharm); human clinical use with limited-quality evidence (small, mostly Russian-language studies; no Western RCT; not FDA/EMA approved) Cortexin is a purified peptide preparation extracted from cattle and pig cerebral cortex tissue — a low-molecular-weight neuropeptide complex used clinically in Russia and Eastern Europe for cognitive impairment, post-stroke recovery, encephalopathy, attention disorders, and pediatric developmental conditions. Like Cerebrolysin, Cortexin is positioned as a broad-spectrum neurotrophic preparation supplying bioactive peptides that mimic endogenous neurotrophic factors. t½ ~2-3 hours (estimated from analog peptide preparations) 18 PubMed View Profile ](/compound/cortexin)[ ### NA-Semax Nootropic Peptide Preclinical NA-Semax is the N-acetyl-l-aspartyl variant of Semax — the original ACTH(4-7) Pro-Gly-Pro analog developed at the Russian Academy of Sciences in the 1990s. t½ ~20-30 minutes (intranasal, estimated from analog data) 3 PubMed View Profile ](/compound/na-semax)[ ### NA-Semax Amidate Nootropic Peptide Preclinical NA-Semax Amidate is the C-terminally amidated NA-Semax — the carboxylic acid at the peptide's C-terminus is replaced with an amide group (-NH2), which is reported to further extend metabolic half-life by resisting carboxypeptidase cleavage in addition to the aminopeptidase resistance the N-acetyl group already provides. The practical effect is a peptide with dosing-frequency use: where standard Semax often requires 3-4 daily doses to maintain effect, NA-Semax Amidate is reported (in vendor monographs and community usage) to maintain subjective effects on a 1-2x daily schedule. t½ ~30-45 minutes (estimated, longer than standard Semax) 2 PubMed View Profile ](/compound/na-semax-amidate)[ ### P-21 Nootropic Peptide Preclinical P-21 is a synthetic cyclic dipeptide — Cyclo(L-prolyl-glycine) — derived from the Selank/Semax C-terminal Pro-Gly-Pro motif. t½ Not formally characterized in published work. P021 has only been studied in rodents (oral/dietary and subcutaneous dosing); no human pharmacokinetic data exist. 4 PubMed View Profile ](/compound/p21) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-adalank) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋